Go to Top

Biotech News

SANUWAVE (SNWV): U.S. Patent to Sterilize Blood Using SNWV’s Shock Wave Technology

SANUWAVE Health, Inc. (OTCBB:SNWV) has received a patent issued by the U.S. Patent and Trademark Office entitled “Method and Devices for Cleaning and Sterilization with Shock Waves.” The claims of the patent (patent number 8,343,420) relate to a new method that sterilizes blood by applying external shock waves to destroy blood pathogens contained in bags, …Read More

BioCryst Pharmaceuticals (BCRX): Update Regarding Peramivir

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and inflammatory diseases. BioCryst announced that it received a preliminary comment letter from the FDA that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory approval of its drug candidate intravenous …Read More

Cell Therapeutics, Inc.(CTIC): $15MM Loan Financing Agreement

Cell Therapeutics, Inc.  (CTIC) announced that it has entered into a Loan and Security Agreement with Hercules Technology Growth Capital, Inc. for a senior secured term loan of up to $15 million. The first $10 million of the term loan was funded on March 27, 2013, and the remaining $5 million is available at the …Read More

Oncolytics Biotech (ONCY): Positive REOLSYIN Clinical Trial Data from Phase 2 Study

Oncolytics Biotech Inc. (NASDAQ: ONCY) is focused on the development of oncolytic viruses for use as cancer therapeutics. The Company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus, is currently in late stage (Phase III) clinical testing in head and neck cancers. REOLYSIN® has been utilized in nearly thirty clinical trials including translational, Phase I, …Read More

Imprimis Pharmaceuticals (IMMY): Pricing of Public Offering at $5.25 per Share

Imprimis Pharmaceuticals, Inc. (IMMY) is a specialty pharmaceutical company focused on the commercial development of compounded drug formulations. Through an exclusive strategic relationship with the largest compounding pharmacy organization in North America, Imprimis expects to use its proprietary Accudel drug delivery technology, coupled with licensed technologies, and proprietary formulations and market data, to identify pharmaceutical …Read More

OXiGENE (OXGN): ZYBRESTAT Plus Avastin Well Tolerated in Second Interim Toxicity Analysis of a Phase 2 Trial

OXiGENE, Inc. (Nasdaq :OXGN)  is a biopharmaceutical company whose mission is finding and developing new and improved therapeutics that can deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions. OXGN announced that the randomized Phase 2 study evaluating the combination of ZYBRESTAT (fosbretabulin tromethamine or CA4P) and Avastin (bevacizumab) to …Read More

Exelixis (EXEL): CEO to Present at the 15th Annual BIO CEO and Investor Conference

Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ (cabozantinib) and has also established a portfolio of other novel compounds, many of which are being advanced by partners as part of collaborations. Michael …Read More

CEL-SCI Corp (CVM): New Investigational Breast Cancer Vaccine

CEL-SCI Corporation (CVM) is a biotechnology company, was formed in 1983. CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases. The Company’s core capabilities include: drug discovery, research, development and manufacturing of complex biological substances. CEL-SCI announced that its longstanding collaboration with Northeast Ohio Medical …Read More

ARCA biopharma, Inc. (ABIO): Phase 3 Trial for Gencaro in Atrial Fibrillation

ARCA biopharma, Inc. (NASDAQ: ABIO) is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the prevention of atrial fibrillation and treatment of heart failure in patients with heart failure and reduced left ventricular ejection fraction …Read More

Keryx Biopharmaceuticals (KERX): Zerenex Meets Primary and All Key Secondary Endpoints in Phase 3 Study

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. KERX today announced that its ferric iron-based phosphate …Read More